1 / 85

Rheumatology in the ICU

Rheumatology in the ICU. Eduardo Santiago M.D 05/16/2012. Airways Problems in Rheumatologic Disorders. Synovial joints: CA and CT. Laryngeal Involvement in RA. Cricoarytenoid joint arthritis . Long standing RA but also in newly diagnosed patients. Prevalence : 40 %-88%.

ulric
Download Presentation

Rheumatology in the ICU

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rheumatology in the ICU Eduardo Santiago M.D 05/16/2012

  2. Airways Problems in Rheumatologic Disorders

  3. Synovial joints: CA and CT

  4. Laryngeal Involvement in RA • Cricoarytenoid joint arthritis. • Long standing RA but also in newly diagnosed patients. • Prevalence: 40%-88%. • Acute or chronic process with slow progression of airflow obstruction. • Fiberopticendoscopy is most sensitive: flexible rhino laryngoscopy.

  5. Laryngeal Involvement in RA • Intubation can lead to mucosal edema, compromise of airway caliber and stridor and airway obstruction post extubation. • Risk Factors: Laxity of joint capsule and large synovial folds.

  6. Treatment • Severe airway obstruction: Secure airways in OR, Surgeon support, awake fiber optic intubation. • Helium/oxygen mixture improve airflow. • Acute: systemic glucocorticoids, local periarticular steroids can improve CA function. • Chronic: surgery: lateralizing one of the vocal folds, arytenoidectomy vs. tracheostomy.

  7. Atlantoaxial instability • C1-C2 instability causing brain stem or spinal cord compression. • Prevalence: 25%. • Independent of disease duration or patient’s age but is most common in patients with severe peripheral joint involvement. • Ligamentous laxity induced by inflammation.

  8. Atlantoaxial instability • High risk of neurologic injury for cervical manipulation in RA patients. • Avoiding hyperextension and maintaining cervical spine in midline w/o extension. • Awake fiberoptic intubation is recommended.

  9. Wegener Granulomatosis • Major upper airway life threatening complication. • Subglottic stenosis prevalence: 20%. • Acute inflammation or scar formation. • Corticosteroids, immunosuppression, intralesional steroids. • Tracheostomy. • Intratracheal dilation injection ( intralesional long acting corticosteroid injection and mechanical dialtion).

  10. Relapsing Polycondritis • Recurrent episodes of inflammation of cartilaginous and connective tissue structures. • Type II collagenous antibodies. • Respiratory involvement associated with high mortality. • Compromise of glottic, supra or subglottic, trachea and first and second order bronchi.

  11. Relapsing Polycondritis • Encroachment of airway by inflammatory swelling. • Formation of mass of fibrous tissue. • Dissolution of tracheobronchial with subsequent collapse during respiration. • Corticosteroids ( MTP ) and immunosuppression, plasmapheresis. • Surgery: tracheostomy in cases of subglottic involvement. • Endotracheal prostheses and stents.

  12. Pulmonary Renal Syndromes in ICU

  13. Anti GBM Disease • Acute Pulmonary hemorrhage, oliguric acute renal failure and anti GBM antibodies. • 1 case per 2 million white people.

  14. Anti GBM Disease • Type IV collagen. • Alpha chains: alpha1 to 6. • Alpha 3: lung, kidney, seminiferous duct, choroids plexus, optic lens and inner ear. • Autoimmune response to Alpha-3 NC-domain: Anti GBM Syndrome. • Genetic susceptibility: HL DR15, HLA DR 4

  15. Pathogenesis

  16. Anti GBM Disease • Anti GBM antibodies ( anti alpha-3, Type IV antibodies). • Double positive: Anti GBM and ANCA p or ANCA c. • 20%-30% of Anti GBM are double positive, >75% ANCA p positive. • 8-10% ANCA vasculitis are double positive.

  17. Anti GBM Disease • Hemoptysis: severity is variable. • Alveolar hemorrhage: infectious and non infectious, cigarretesmoking. • HLM in alveolar and small airways, interstitial infiltrates, lymphocytic infiltration in alveolar septae and peribroncovascularinterstitium. • DAD: proteinaceous infiltrates and hyaline membranes.

  18. Anti GBM Disease • Crescent formation and GBM destruction. • Epithelial crescents in more than 50% of the glomeruli is a poor prognostic factor.

  19. Therapy • Pulse methylprednisolone, cyclophosphamide and plasmapheresis. • MP: 30mg/kg, on alternate days for 3 doses. Follow by oral prednisone for 12 months. • CP: 2mg/kg, daily dose, should be reduced by 0.5mg/kg every 3 months. • Plasma exchange: 4 liter plasma exchanges daily or on alternate days.

  20. Small Vessel Vasculitis • Wegener's: c-ANCA or PR3 ANCA (65%) or p-ANCA or MPO ANCA (20%). • Microscopic Polyangiitis and CCS: p-ANCA or MPO ANCA.

  21. Treatment • Accurate determination of disease severety. • Remission induction phase. • Maintenance phase.

  22. Treatment • Induction therapy: MP IV 7mg/kg on 3 consecutive days, then prednisone 1mg/kg per day for 1 month, alternate date schedule and the dose is reduced by 10mg/week on the second month. • IV Cyclophosphamide: 0.5mg/kg at monthly intervals ( less side effects than oral) • Oral Cyclophosphamide: 2mg/kg per day.

  23. Treatment • Rituximab (anti CD 20 chimeric monoclonal antibody). • Infliximab. • Plasma exchange or plasmapheresis, twice daily for 7 days in patients with significant pulmonary hemorrhage and renal failure. • IVIG in severe pulmonary hemorrhage.

  24. Catastrophic Antiphospholipid Syndrome • APLS: Thrombosis, thrombocytopenia, recurrent fetal loss and increased APL antibodies. • CAPS: subset characterize with fulminant clinical course with widespread vascular occlusion involving at least three organs in association with ACL or LA. • Thrombocytopenia and MAHA.

  25. Pathology and Pathophysiology • Non inflammatory, thrombotic microangiopathy of small vessels resulting in MOF. • APL: immunoglobulins that bind plasma proteins or phospholipid micro particles. • Activation of platelets, monocytes, tumor cells or endothelial cells leading to pro coagulant state.

  26. Role of APL antibodies • Tissue ischemia and necrosis leading to SIRS. • SIRS= altered hemostasis, increased coagulation and microvascular fibrin deposition.

  27. Catastrophic Antiphospholipid Syndrome • Prior history of APS in 50% to 70%. • Precipitating factors are found in 22%. • Infections, trauma, surgical procedures, tissue biopsies, pregnancy and post fetal demise, malignancy, withdrawal from anticoagulation.

  28. Catastrophic Antiphospholipid Syndrome • Diffuse injury to the capillary endothelial and epithelial cells resulting in ALI and ARDS. • Microvascular thrombi causing endothelial damage, neutrophil influx and cytokines release. • Alveolar hemorrhage .

  29. Catastrophic Antiphospholipid Syndrome • Valvular vegetations. • Coronary artery occlusion with cardiac failure and circulatory collapse. • Thrombus formation within the cardiac chambers.

  30. Catastrophic Antiphospholipid Syndrome • Renal thrombotic microangiopathy of the glomerular capillaries and small renal arteries.

  31. Treatment • Anticoagulation and r/o infection. • Steroids, plasmapheresis, IVIG. • Plasmaphresis: removal of B2GPI, cytokines and mediators that promote coagulation.

  32. SLE

  33. SLE • Infections is the most common form of pulmonary involvement. • Lupus Pneumonitis. • Alveolar Hemorrhage. • Acute Reversible Hypoxemia. • Shrinking Lung Syndrome. • Drug Reaction.

  34. Acute Lupus Pneumonitis • Exclusion diagnosis. Clinical diagnosis. • Dyspnea, cough, fever and hemoptysis. • R/O infection. • Incidence: 0.9-12%. • Initial presentation or in patients who have been already diagnosed with SLE. • Mortality: 50%

More Related